Suzhou Ribo Life Science (6938) Stock Overview
Researches and develops small nucleic acid drugs for treating cardiovascular, metabolic, renal, liver, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
6938 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Suzhou Ribo Life Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$64.70 |
| 52 Week High | HK$95.80 |
| 52 Week Low | HK$51.20 |
| Beta | 0 |
| 1 Month Change | 7.39% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -21.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6938 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 12.9% | 9.7% | 1.6% |
| 1Y | n/a | 108.5% | 30.1% |
Return vs Industry: Insufficient data to determine how 6938 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 6938 performed against the Hong Kong Market.
Price Volatility
| 6938 volatility | |
|---|---|
| 6938 Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 6938 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 6938's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 407 | Zicai Liang | www.ribolia.com |
Suzhou Ribo Life Science Co., Ltd. researches and develops small nucleic acid drugs for treating cardiovascular, metabolic, renal, liver, and other diseases. It develops RBD4059 for treating thrombotic diseases; RBD5044 for treating hypertrigly ceridemia; RBD7022 for treating Hypercho lesterolemia; RBD1016 for treating CHB and CHD that are in Phase II clinical trials.
Suzhou Ribo Life Science Co., Ltd. Fundamentals Summary
| 6938 fundamental statistics | |
|---|---|
| Market cap | HK$11.03b |
| Earnings (TTM) | -HK$316.62m |
| Revenue (TTM) | HK$169.10m |
Is 6938 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6938 income statement (TTM) | |
|---|---|
| Revenue | CN¥148.51m |
| Cost of Revenue | CN¥13.48m |
| Gross Profit | CN¥135.03m |
| Other Expenses | CN¥413.09m |
| Earnings | -CN¥278.06m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 90.93% |
| Net Profit Margin | -187.23% |
| Debt/Equity Ratio | 1,951.2% |
How did 6938 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/07 09:29 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Suzhou Ribo Life Science Co., Ltd. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Wangbin Zhou | Citigroup Inc |
| Haoyuan Zhang | ICBC International Research |